1530 Stock Overview
An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
3SBio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$6.34 |
| 52 Week High | HK$7.85 |
| 52 Week Low | HK$4.91 |
| Beta | 0.71 |
| 1 Month Change | 4.79% |
| 3 Month Change | 0.79% |
| 1 Year Change | 7.46% |
| 3 Year Change | 1.44% |
| 5 Year Change | -42.36% |
| Change since IPO | -32.19% |
Recent News & Updates
3SBio Inc. (HKG:1530) Screens Well But There Might Be A Catch
Jan 17
3SBio's (HKG:1530) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Oct 083SBio Inc.'s (HKG:1530) P/E Is Still On The Mark Following 34% Share Price Bounce
Oct 07Recent updates
3SBio Inc. (HKG:1530) Screens Well But There Might Be A Catch
Jan 173SBio's (HKG:1530) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Oct 083SBio Inc.'s (HKG:1530) P/E Is Still On The Mark Following 34% Share Price Bounce
Oct 07We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt
Sep 26Shareholders Will Probably Hold Off On Increasing 3SBio Inc.'s (HKG:1530) CEO Compensation For The Time Being
Jun 19There's Reason For Concern Over 3SBio Inc.'s (HKG:1530) Price
May 21Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly
Apr 16Pinning Down 3SBio Inc.'s (HKG:1530) P/E Is Difficult Right Now
Jan 26These 4 Measures Indicate That 3SBio (HKG:1530) Is Using Debt Safely
Dec 30Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?
Dec 11Is 3SBio (HKG:1530) A Risky Investment?
Sep 12Calculating The Fair Value Of 3SBio Inc. (HKG:1530)
Aug 07With EPS Growth And More, 3SBio (HKG:1530) Makes An Interesting Case
Jul 193SBio (HKG:1530) Has A Pretty Healthy Balance Sheet
Apr 13Is Now The Time To Put 3SBio (HKG:1530) On Your Watchlist?
Feb 27Is 3SBio Inc. (HKG:1530) Trading At A 23% Discount?
Jan 17Do 3SBio's (HKG:1530) Earnings Warrant Your Attention?
Nov 24We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease
Oct 213SBio Inc. (HKG:1530) Shares Could Be 49% Below Their Intrinsic Value Estimate
Oct 04Is 3SBio Inc. (HKG:1530) Trading At A 45% Discount?
Apr 21We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease
Mar 31We Think 3SBio (HKG:1530) Can Manage Its Debt With Ease
Dec 09An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 50% Undervalued
Nov 21We Think 3SBio (HKG:1530) Can Stay On Top Of Its Debt
Sep 103SBio Inc. (HKG:1530) Shares Could Be 38% Below Their Intrinsic Value Estimate
Aug 223SBio Inc.'s (HKG:1530) Intrinsic Value Is Potentially 48% Above Its Share Price
May 21Here's Why 3SBio (HKG:1530) Can Manage Its Debt Responsibly
Apr 16What Kind Of Shareholders Hold The Majority In 3SBio Inc.'s (HKG:1530) Shares?
Mar 11Is 3SBio Inc.'s (HKG:1530) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Feb 18
An Intrinsic Calculation For 3SBio Inc. (HKG:1530) Suggests It's 38% Undervalued
Jan 31A Look At 3SBio's (HKG:1530) Share Price Returns
Jan 03Are Insiders Buying 3SBio Inc. (HKG:1530) Stock?
Dec 16What Is The Ownership Structure Like For 3SBio Inc. (HKG:1530)?
Dec 01Shareholder Returns
| 1530 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 10.1% | 1.9% | 3.4% |
| 1Y | 7.5% | 5.6% | 28.0% |
Return vs Industry: 1530 exceeded the Hong Kong Biotechs industry which returned 5.6% over the past year.
Return vs Market: 1530 underperformed the Hong Kong Market which returned 28% over the past year.
Price Volatility
| 1530 volatility | |
|---|---|
| 1530 Average Weekly Movement | 4.7% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in HK Market | 13.9% |
| 10% least volatile stocks in HK Market | 3.0% |
Stable Share Price: 1530 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1530's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 5,607 | Jing Lou | www.3sbio.com |
3SBio Inc., an investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally. The company provides TPIAO, a recombinant human thrombopoietin to treat chemotherapy-induced thrombopenia and immune thrombocytopenia; Cipterbin, an anti-HER2 monoclonal antibody for the treatment of HER2-positive metastatic breast cancer; TNF, pre-filled aqueous injection solution. It also offers YISAIPU, the receptor fusion tumor necrosis factor inhibitor; Mandi-minoxidil tincture, an OTC external medicine for treating hair loss; EPIAO and SEPO, an erythropoietin injection; SPARIN, an injectable low-molecular-weight heparin calcium.
3SBio Inc. Fundamentals Summary
| 1530 fundamental statistics | |
|---|---|
| Market cap | HK$15.00b |
| Earnings (TTM) | HK$1.78b |
| Revenue (TTM) | HK$9.01b |
8.4x
P/E Ratio1.7x
P/S RatioIs 1530 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1530 income statement (TTM) | |
|---|---|
| Revenue | CN¥8.42b |
| Cost of Revenue | CN¥1.18b |
| Gross Profit | CN¥7.24b |
| Other Expenses | CN¥5.58b |
| Earnings | CN¥1.66b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.70 |
| Gross Margin | 85.94% |
| Net Profit Margin | 19.69% |
| Debt/Equity Ratio | 24.7% |
How did 1530 perform over the long term?
See historical performance and comparisonDividends
3.8%
Current Dividend Yield33%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 12:14 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
3SBio Inc. is covered by 33 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ruyi Tang | BOCI Research Ltd. |
| Sharon Shi | BOCI Research Ltd. |
| Difei Yang | Capstone Investments |